Published Date: 08 May 2024
This week, the multinational pharmaceutical company AstraZeneca acknowledged in court that the COVID-19 vaccine may result in a rare but fatal blood clotting condition. This information is now at the center of a potentially $125 million class-action lawsuit.
Read Full NewsFindings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation